Briefly, according to international guidelines, the first-line treatment for advanced HER2-positive breast cancer (ABC) consists of a combination of taxane-based chemotherapy with dual HER2-blockade with pertuzumab and trastuzumab [3,4]. Here, ERBB2 is linked to breast carcinoma.